-
Je něco špatně v tomto záznamu ?
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
SS. Wang, M. Carrington, SI. Berndt, SL. Slager, PM. Bracci, J. Voutsinas, JR. Cerhan, KE. Smedby, H. Hjalgrim, J. Vijai, LM. Morton, R. Vermeulen, O. Paltiel, CM. Vajdic, MS. Linet, A. Nieters, S. de Sanjose, W. Cozen, EE. Brown, J. Turner, JJ....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
Grantová podpora
CIHR - Canada
Cancer Research UK - United Kingdom
HHSN261201000140C
NCI NIH HHS - United States
R01 CA092153
NCI NIH HHS - United States
R01 CA149445
NCI NIH HHS - United States
P30 CA016087
NCI NIH HHS - United States
R01 CA049449
NCI NIH HHS - United States
R01 CA200703
NCI NIH HHS - United States
P30 CA042014
NCI NIH HHS - United States
N01CO12400
NCI NIH HHS - United States
R01 CA062006
NCI NIH HHS - United States
N01 PC067009
NCI NIH HHS - United States
HHSN261201000026C
NCI NIH HHS - United States
R01 CA098661
NCI NIH HHS - United States
P01 CA087969
NCI NIH HHS - United States
U01 HG007033
NHGRI NIH HHS - United States
U01 CA118444
NCI NIH HHS - United States
P30 CA086862
NCI NIH HHS - United States
R01 CA134674
NCI NIH HHS - United States
R01 CA148690
NCI NIH HHS - United States
HHSN261201000035I
NCI NIH HHS - United States
U01 CA167552
NCI NIH HHS - United States
P30 CA015083
NCI NIH HHS - United States
R03 CA179558
NCI NIH HHS - United States
HHSN261201500005C
NCI NIH HHS - United States
HHSN261201000034C
NCI NIH HHS - United States
HHSN261201000035C
NCI NIH HHS - United States
U58 DP000807
NCCDPHP CDC HHS - United States
UL1 TR000135
NCATS NIH HHS - United States
N01 PC067008
NCI NIH HHS - United States
R01 CA154643
NCI NIH HHS - United States
N01 PC067010
NCI NIH HHS - United States
HHSN261200800001C
CCR NIH HHS - United States
UM1 CA186107
NCI NIH HHS - United States
U01 CA049449
NCI NIH HHS - United States
K08 CA134919
NCI NIH HHS - United States
P30 ES000260
NIEHS NIH HHS - United States
UM1 CA167552
NCI NIH HHS - United States
R21 CA165923
NCI NIH HHS - United States
R01 CA098122
NCI NIH HHS - United States
N01 PC065064
NCI NIH HHS - United States
P50 CA097274
NCI NIH HHS - United States
P30 CA033572
NCI NIH HHS - United States
HHSN261200800001E
NCI NIH HHS - United States
NLK
Free Medical Journals
od 1941 do Před 1 rokem
Freely Accessible Science Journals
od 1941 do Před 1 rokem
Open Access Digital Library
od 1941-01-01
Open Access Digital Library
od 1941-01-01
- MeSH
- celogenomová asociační studie metody MeSH
- genetická heterogenita MeSH
- heterozygot MeSH
- histokompatibilita - antigeny třídy I genetika MeSH
- histokompatibilita - antigeny třídy II genetika MeSH
- lidé MeSH
- nehodgkinský lymfom genetika MeSH
- prospektivní studie MeSH
- studie případů a kontrol MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, N.I.H., Intramural MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Research Support, U.S. Gov't, P.H.S. MeSH
A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086-96. ©2018 AACR.
Bill Lyons Informatics Centre UCL Cancer Institute University College London London United Kingdom
Cancer Epidemiology and Intelligence Division Cancer Council Victoria Melbourne Australia
Cancer Epidemiology Unit University of Oxford Oxford United Kingdom
Cancer Research Center of Lyon INSERM UMR1052 Center Léon Bérard Lyon France
Department of Biomedical Science University of Cagliari Monserrato Cagliari Italy
Department of Epidemiology School of Public Health Brown University Providence Rhode Island
Department of Family Medicine and Public Health Sciences Wayne State University Detroit Michigan
Department of Health Sciences Research Mayo Clinic Rochester Minnesota
Department of Health Sciences University of York York United Kingdom
Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta Georgia
Department of Hematology Rishospitalet Copenhagen Denmark
Department of Immunology CHU Henri Mondor Créteil France
Department of Immunology Genetics and Pathology Uppsala University Uppsala Sweden
Department of Internal Medicine Carver College of Medicine The University of Iowa Iowa City Iowa
Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota
Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden
Department of Medicine Memorial Sloan Kettering Cancer Center New York City New York
Department of Pathology City of Hope Duarte California
Department of Population Sciences Beckman Research Institute and the City of Hope Duarte California
Department of Public Health Clinical and Molecular Medicine University of Cagliari Cagliari Italy
Division of Cancer Epidemiology and Genetics NCI Bethesda Maryland
Division of Clinical Epidemiology German Cancer Research Centre Heidelberg Baden Württemberg Germany
Division of Hematology S Francesco Hospital Nuoro Italy
Epidemiology Research Program American Cancer Society Atlanta Georgia
International Agency for Research on Cancer Lyon France
School of Nursing and Human Sciences Dublin City University Dublin Ireland
School of Public Health Imperial College London London United Kingdom
Sydney School of Public Health The University of Sydney Sydney Australia
The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York City New York
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035262
- 003
- CZ-PrNML
- 005
- 20191014085813.0
- 007
- ta
- 008
- 191007s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1158/0008-5472.CAN-17-2900 $2 doi
- 035 __
- $a (PubMed)29735552
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Wang, Sophia S $u Department of Population Sciences, Beckman Research Institute and the City of Hope, Duarte, California. sowang@coh.org.
- 245 10
- $a HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes / $c SS. Wang, M. Carrington, SI. Berndt, SL. Slager, PM. Bracci, J. Voutsinas, JR. Cerhan, KE. Smedby, H. Hjalgrim, J. Vijai, LM. Morton, R. Vermeulen, O. Paltiel, CM. Vajdic, MS. Linet, A. Nieters, S. de Sanjose, W. Cozen, EE. Brown, J. Turner, JJ. Spinelli, T. Zheng, BM. Birmann, CR. Flowers, N. Becker, EA. Holly, E. Kane, D. Weisenburger, M. Maynadie, P. Cocco, D. Albanes, SJ. Weinstein, LR. Teras, WR. Diver, SJ. Lax, RC. Travis, R. Kaaks, E. Riboli, Y. Benavente, P. Brennan, J. McKay, MH. Delfau-Larue, BK. Link, C. Magnani, MG. Ennas, G. Latte, AL. Feldman, NW. Doo, GG. Giles, MC. Southey, RL. Milne, K. Offit, J. Musinsky, AA. Arslan, MP. Purdue, HO. Adami, M. Melbye, B. Glimelius, L. Conde, NJ. Camp, M. Glenn, K. Curtin, J. Clavel, A. Monnereau, DG. Cox, H. Ghesquières, G. Salles, P. Bofetta, L. Foretova, A. Staines, S. Davis, RK. Severson, Q. Lan, A. Brooks-Wilson, MT. Smith, E. Roman, A. Kricker, Y. Zhang, P. Kraft, SJ. Chanock, N. Rothman, P. Hartge, CF. Skibola,
- 520 9_
- $a A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086-96. ©2018 AACR.
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická heterogenita $7 D018740
- 650 _2
- $a celogenomová asociační studie $x metody $7 D055106
- 650 _2
- $a heterozygot $7 D006579
- 650 _2
- $a histokompatibilita - antigeny třídy I $x genetika $7 D015395
- 650 _2
- $a histokompatibilita - antigeny třídy II $x genetika $7 D000949
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nehodgkinský lymfom $x genetika $7 D008228
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prospektivní studie $7 D011446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a Research Support, N.I.H., Intramural $7 D052060
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
- 655 _2
- $a Research Support, U.S. Gov't, P.H.S. $7 D013487
- 700 1_
- $a Carrington, Mary $u Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, and Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
- 700 1_
- $a Berndt, Sonja I $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Slager, Susan L $u Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Bracci, Paige M $u Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.
- 700 1_
- $a Voutsinas, Jenna $u Department of Population Sciences, Beckman Research Institute and the City of Hope, Duarte, California.
- 700 1_
- $a Cerhan, James R $u Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Smedby, Karin E $u Department of Medicine Solna, unit of clinical epidemiology, Karolinska Institutet, Stockholm, Sweden. Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Hjalgrim, Henrik $u Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark. Department of Hematology, Rishospitalet, Copenhagen, Denmark.
- 700 1_
- $a Vijai, Joseph $u Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.
- 700 1_
- $a Morton, Lindsay M $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Vermeulen, Roel $u Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
- 700 1_
- $a Paltiel, Ora $u Braun School of Public Health and Community Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- 700 1_
- $a Vajdic, Claire M $u Centre for Big Data Research in Health, The University of New South Wales, Sydney, New South Wales, Australia.
- 700 1_
- $a Linet, Martha S $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Nieters, Alexandra $u Centre for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany.
- 700 1_
- $a de Sanjose, Silvia $u Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d' Oncologia, IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- 700 1_
- $a Cozen, Wendy $u Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Departments of Preventive Medicine and Pathology, University of Southern California, Los Angeles, Calfornia.
- 700 1_
- $a Brown, Elizabeth E $u Department of Pathology, School of Medicine and the UAB Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama.
- 700 1_
- $a Turner, Jennifer $u Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, Australia. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
- 700 1_
- $a Spinelli, John J $u Cancer Control Research, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
- 700 1_
- $a Zheng, Tongzhang $u Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.
- 700 1_
- $a Birmann, Brenda M $u Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
- 700 1_
- $a Flowers, Christopher R $u Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
- 700 1_
- $a Becker, Nikolaus $u Division of Clinical Epidemiology, German Cancer Research Centre, Heidelberg, Baden-Württemberg, Germany.
- 700 1_
- $a Holly, Elizabeth A $u Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.
- 700 1_
- $a Kane, Eleanor $u Department of Health Sciences, University of York, York, United Kingdom.
- 700 1_
- $a Weisenburger, Dennis $u Department of Pathology, City of Hope, Duarte, California.
- 700 1_
- $a Maynadie, Marc $u Registry of Hematological Malignancies of Cote d'Or, INSERM UMR1231, University of Burgundy and Dijon University Hospital, Dijon, France.
- 700 1_
- $a Cocco, Pierluigi $u Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Albanes, Demetrius $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Weinstein, Stephanie J $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Teras, Lauren R $u Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
- 700 1_
- $a Diver, W Ryan $u Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.
- 700 1_
- $a Lax, Stephanie J $u Department of Health Sciences, University of York, York, United Kingdom.
- 700 1_
- $a Travis, Ruth C $u Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
- 700 1_
- $a Kaaks, Rudolph $u Division of Clinical Epidemiology, German Cancer Research Centre, Heidelberg, Baden-Württemberg, Germany.
- 700 1_
- $a Riboli, Elio $u School of Public Health, Imperial College London, London, United Kingdom.
- 700 1_
- $a Benavente, Yolanda $u Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Institut Català d' Oncologia, IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- 700 1_
- $a Brennan, Paul $u International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a McKay, James $u Department of Immunology, CHU Henri Mondor, Créteil, France.
- 700 1_
- $a Delfau-Larue, Marie-Hélène $u Department of Immunology, CHU Henri Mondor, Créteil, France. INSERM U 955, CHU Henri Mondor, Créteil, France.
- 700 1_
- $a Link, Brian K $u Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa.
- 700 1_
- $a Magnani, Corrado $u Center of Oncological Prevention (CPO) Piemonte and Unit of Medical Statistics and Epidemiology, Department Translational Medicine, University of Piemonte Orientale, Novara, Italy.
- 700 1_
- $a Ennas, Maria Grazia $u Department of Biomedical Science, University of Cagliari, Monserrato, Cagliari, Italy.
- 700 1_
- $a Latte, Giancarlo $u Division of Hematology, S. Francesco Hospital, Nuoro, Italy.
- 700 1_
- $a Feldman, Andrew L $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
- 700 1_
- $a Doo, Nicole Wong $u Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
- 700 1_
- $a Giles, Graham G $u Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
- 700 1_
- $a Southey, Melissa C $u Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia.
- 700 1_
- $a Milne, Roger L $u Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
- 700 1_
- $a Offit, Kenneth $u Department of Hematology, Rishospitalet, Copenhagen, Denmark.
- 700 1_
- $a Musinsky, Jacob $u Department of Hematology, Rishospitalet, Copenhagen, Denmark.
- 700 1_
- $a Arslan, Alan A $u Department of Obstetrics and Gynecology, New York University School of Medicine, New York City, New York. Department of Environmental Medicine, New York University School of Medicine, New York City, New York. Perlmutter Cancer Center, NYU Langone Medical Center, New York City, New York.
- 700 1_
- $a Purdue, Mark P $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Adami, Hans-Olov $u Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Melbye, Mads $u Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark. Department of Medicine, Stanford University School of Medicine, Stanford, Calfornia.
- 700 1_
- $a Glimelius, Bengt $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Conde, Lucia $u Bill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, United Kingdom.
- 700 1_
- $a Camp, Nicola J $u Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
- 700 1_
- $a Glenn, Martha $u Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
- 700 1_
- $a Curtin, Karen $u Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
- 700 1_
- $a Clavel, Jacqueline $u Epidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. Université Paris Descartes, Paris, France.
- 700 1_
- $a Monnereau, Alain $u Université Paris Descartes, Paris, France. Université Paris Descartes, Paris, France. Registre des hémopathies malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, UMR 1219, France.
- 700 1_
- $a Cox, David G $u Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom; Cancer Research Center of Lyon, INSERM UMR1052, Center Léon Bérard, Lyon, France.
- 700 1_
- $a Ghesquières, Hervé $u Université Paris Descartes, Paris, France. Laboratoire de Biologie Moléculaire de la Cellule UMR 5239, Centre National de la Recherche Scientifique, Pierre benite Cedex, France.
- 700 1_
- $a Salles, Gilles $u Laboratoire de Biologie Moléculaire de la Cellule UMR 5239, Centre National de la Recherche Scientifique, Pierre benite Cedex, France. Department of Hematology, Hospices Civils De Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard, Lyon, France.
- 700 1_
- $a Bofetta, Paulo $u The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.
- 700 1_
- $a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, MF MU, Brno, Czech Republic.
- 700 1_
- $a Staines, Anthony $u School of Nursing and Human Sciences, Dublin City University, Dublin, Ireland.
- 700 1_
- $a Davis, Scott $u Fred Hutchinson Cancer Research Center and School of Public Health and Community Medicine, University of Washington, Seattle, Washington.
- 700 1_
- $a Severson, Richard K $u Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan.
- 700 1_
- $a Lan, Qing $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Brooks-Wilson, Angela $u Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada. Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
- 700 1_
- $a Smith, Martyn T $u Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California.
- 700 1_
- $a Roman, Eve $u Department of Health Sciences, University of York, York, United Kingdom.
- 700 1_
- $a Kricker, Anne $u Sydney School of Public Health, The University of Sydney, Sydney, Australia.
- 700 1_
- $a Zhang, Yawei $u Department of Surgery, Yale School of Medicine, New Haven, Connecticut. Department of Environmental Health Sciences, Yale School of Public Health, New Haven.
- 700 1_
- $a Kraft, Peter $u Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
- 700 1_
- $a Chanock, Stephen J $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Rothman, Nathaniel $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Hartge, Patricia $u Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
- 700 1_
- $a Skibola, Christine F $u Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
- 773 0_
- $w MED00009437 $t Cancer research $x 1538-7445 $g Roč. 78, č. 14 (2018), s. 4086-4096
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29735552 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014090237 $b ABA008
- 999 __
- $a ok $b bmc $g 1451922 $s 1073812
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 78 $c 14 $d 4086-4096 $e 20180507 $i 1538-7445 $m Cancer research $n Cancer Res $x MED00009437
- GRA __
- $p CIHR $2 Canada
- GRA __
- $p Cancer Research UK $2 United Kingdom
- GRA __
- $a HHSN261201000140C $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA092153 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA149445 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA016087 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA049449 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA200703 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA042014 $p NCI NIH HHS $2 United States
- GRA __
- $a N01CO12400 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA062006 $p NCI NIH HHS $2 United States
- GRA __
- $a N01 PC067009 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261201000026C $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA098661 $p NCI NIH HHS $2 United States
- GRA __
- $a P01 CA087969 $p NCI NIH HHS $2 United States
- GRA __
- $a U01 HG007033 $p NHGRI NIH HHS $2 United States
- GRA __
- $a U01 CA118444 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA086862 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA134674 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA148690 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261201000035I $p NCI NIH HHS $2 United States
- GRA __
- $a U01 CA167552 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA015083 $p NCI NIH HHS $2 United States
- GRA __
- $a R03 CA179558 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261201500005C $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261201000034C $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261201000035C $p NCI NIH HHS $2 United States
- GRA __
- $a U58 DP000807 $p NCCDPHP CDC HHS $2 United States
- GRA __
- $a UL1 TR000135 $p NCATS NIH HHS $2 United States
- GRA __
- $a N01 PC067008 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA154643 $p NCI NIH HHS $2 United States
- GRA __
- $a N01 PC067010 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261200800001C $p CCR NIH HHS $2 United States
- GRA __
- $a UM1 CA186107 $p NCI NIH HHS $2 United States
- GRA __
- $a U01 CA049449 $p NCI NIH HHS $2 United States
- GRA __
- $a K08 CA134919 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 ES000260 $p NIEHS NIH HHS $2 United States
- GRA __
- $a UM1 CA167552 $p NCI NIH HHS $2 United States
- GRA __
- $a R21 CA165923 $p NCI NIH HHS $2 United States
- GRA __
- $a R01 CA098122 $p NCI NIH HHS $2 United States
- GRA __
- $a N01 PC065064 $p NCI NIH HHS $2 United States
- GRA __
- $a P50 CA097274 $p NCI NIH HHS $2 United States
- GRA __
- $a P30 CA033572 $p NCI NIH HHS $2 United States
- GRA __
- $a HHSN261200800001E $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20191007
